MAM
UTHR icon

Marquette Asset Management’s United Therapeutics UTHR Stock Holding History

Marquette Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$547K Hold
1,010
– – 0.07% 44
2026
Q1 		$599K Buy
1,010
+200
+25% +$99.6K 0.09% 34
2025
Q4 		$395K Buy
810
+1
+0.1% +$466 0.06% 39
2025
Q3 		$339K Buy
809
+409
+102% +$138K 0.05% 43
2025
Q2 		$115K Buy
+400
New +$120K 0.02% 61

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Marquette Asset Management's UTHR Position: Q2 2026 in Review

Marquette Asset Management held its United Therapeutics (UTHR) position steady in Q2 2026 at 1,010 shares worth $547K. The position accounts for 0.07% of the portfolio, ranked #44.

Marquette Asset Management first reported a position in UTHR in Q2 2025 and has held it in 5 quarters since. The position peaked at $599K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Marquette Asset Management held 1,010 shares of United Therapeutics worth $547K as of Q2 2026.
  • Marquette Asset Management left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.07% of Marquette Asset Management's portfolio in Q2 2026, its #44 holding.
  • Marquette Asset Management first reported a position in United Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Marquette Asset Management's United Therapeutics position peaked at $599K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.